ClassID:

20968

A61K38/2033 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons; Interleukins [IL] IL-5

Recent Application in this class:
#1
20260091063
2026-04-02

METHODS FOR IMPROVING COGNITIVE FUNCTION

#2
20250387480
2025-12-25

METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND AUTOIMMUNE CONDITIONS WITH ECM-AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS

#3
20250339476
2025-11-06

ENGINEERED BACTERIAL THERAPEUTICS FOR THE TREATMENT OF GASTROINTESTINAL DISEASE

#4
20250276028
2025-09-04

COMPOSITION FOR REDUCING SIZE OR VOLUME OF TARGET TISSUE OR KIT INCLUDING SAME

#5
20240226266
2024-07-11

METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS

#6
20230364218
2023-11-16

METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS

#7
20230070595
2023-03-09

Methods and compositions for producing an adenovirus vector for use with multiple vaccinations

#8
20220370593
2022-11-24

Methods and compositions for producing an adenovirus vector for use with multiple vaccinations

#9
20220265809
2022-08-25

Methods and compositions for producing an adenovirus vector for use with multiple vaccinations

#10
20220249613
2022-08-11

CELL CULTURE FOR TREATING DISEASE IN THE LOWER LIMBS

#11
20220249575
2022-08-11

FORMULATION AND TREATMENT FOR OPHTHALMIC DISORDERS

#12
20220125849
2022-04-28

METHODS FOR IMPROVING COGNITIVE FUNCTION

#13
20220118089
2022-04-21

METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND AUTOIMMUNE CONDITIONS WITH ECM-AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS

#14
20210379021
2021-12-09

METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS

#15
20210106651
2021-04-15

BIO-MIMETIC FORMULATION

#16
20200276269
2020-09-03

Eosinophils alleviate lung allograft rejection through their modulation of CD8+ t cells

#17
20200261565
2020-08-20

Methods and compositions for producing an adenovirus vector for use with multiple vaccinations

#18
20190224277
2019-07-25

BIO-MIMETIC FORMULATION

#19
20180104186
2018-04-19

METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPIDERMOLYSIS BULLOSA

#20
20170246216
2017-08-31

Human amniotic fluid preparation having long-term stability

#21
20170065706
2017-03-09

HPV vaccines and methods of use thereof

#22
20170065693
2017-03-09

Breast cancer vaccines and methods of use thereof

#23
20160136205
2016-05-19

TARGETING TYPE I NKT CELLS TO CONTROL INFLAMMATION

#24
20150250823
2015-09-10

Preeclamptic placental mesenchymal stem cell conditioned medium for use in the treatment of a tumour

#25
20140370038
2014-12-18

CD4+ CD25+ T-CELLS ACTIVATED TO A SPECIFIC ANTIGEN

#26
20130302274
2013-11-14

COMBINATION THERAPY

#27
20130224144
2013-08-29

Sequential administration of a replication defective adenovirus vector in vaccination protocols

#28
20120189575
2012-07-26

Oligodendrocyte Production from Multipotent Neural Stem Cells

#29
20100260755
2010-10-14

IBUDILAST AND IMMUNOMODULATORS COMBINATION

#30
20100183673
2010-07-22

Sequential administration of a replication defective adenovirus vector in vaccination protocols

#31
20100135968
2010-06-03

Oligodendrocyte Production From Multipotent Neural Stem Cells

#32
20090214469
2009-08-27

Methods and Compositions for the Treatment of Sepsis

#33
20090074712
2009-03-19

Methods for Treatment and Prevention of Infection

#34
20080279813
2008-11-13

Cd4+ Cd25+ T-cells activated to a specific antigen

#35
20060292115
2006-12-28

Methods and compositions for treating and preventing inflammatory conditions

#36
20060177419
2006-08-10

Stimulating neutrophil function to treat inflammatory bowel disease

#37
20050244965
2005-11-03

Oligodendrocyte production from multipotent neural stem cells

#38
20050169884
2005-08-04

Method of treating Crohn's Disease using sargramostim

#39
20050142102
2005-06-30

Methods of treating neurological conditions with hematopoietic growth factors